This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2013 by Clarus Therapeutics, Inc..
Recruitment status was:  Active, not recruiting
Information provided by (Responsible Party):
Clarus Therapeutics, Inc. Identifier:
First received: September 5, 2012
Last updated: December 17, 2013
Last verified: December 2013
The purpose of this one year extension (follow-up) study is to gather additional safety data in hypogonadal men treated with oral TU or AndroGel who have completed the 12-month Phase III study CLAR-09007.

Condition Intervention Phase
Male Hypogonadism Drug: Oral testosterone undecanoate Drug: Transdermal testosterone gel (AndroGel) Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

Resource links provided by NLM:

Further study details as provided by Clarus Therapeutics, Inc.:

Primary Outcome Measures:
  • Evidence of clinically significant safety related events in each treatment group [ Time Frame: 12 months ]
    Clinical laboratory, prostate volume, and cardiovascular biomarkers

Enrollment: 182
Study Start Date: August 2012
Estimated Study Completion Date: April 2014
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Oral testosterone undecanoate
Oral testosterone undecanoate; continue dose from previous Phase III trial; 100-300 mg T (as TU), BID, for 12 months.
Drug: Oral testosterone undecanoate
Active Comparator: Transdermal testosterone gel (AndroGel)
Transdermal testosterone gel; continue dose from previous Phase III trial, 2.5-10 g/applied once daily for 12 months
Drug: Transdermal testosterone gel (AndroGel)


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Successful completion of CLAR-09007
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01699178

  Hide Study Locations
United States, Alabama
Alabama Clinical Therapeutics, Inc.
Birmingham,, Alabama, United States, 35235
Alabama Internal Medicine, PC
Birmingham, Alabama, United States, 35235
Alabama Clinical Therapeutics
Calera, Alabama, United States, 35040
Medical Affiliated Research Center, Inc
Huntsville, Alabama, United States, 35801
United States, Arizona
Quality of Life Medical and Research Centers, LLC
Tucson, Arizona, United States, 85712
United States, California
Providence Clinical Research
Burbank, California, United States, 91505
South Orange County Endocrinology
Laguna Hills, California, United States, 92653
Tower Urology
Los Angeles, California, United States, 90048
David Geffen School of Medicine, UCLA
Los Angeles, California, United States, 90095
Harbor-UCLA Medical Center, LA Biomedical Research Institute
Torrance, California, United States, 90502
United States, Connecticut
Connecticut Clinical Research Center/ConnecTrials
Middlebury, Connecticut, United States, 06762
University of CT School of Medicine
New Haven, Connecticut, United States, 06511
United States, Florida
South Florida Medical Research
Aventura, Florida, United States, 33180
United States, Kentucky
University of Louisville
Louisville, Kentucky, United States, 40202
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Boston University School of Medicine
Boston, Massachusetts, United States, 02118
United States, New York
Maimonides Medical Center
Brooklyn, New York, United States, 11235
Bruce R. Gilbert, MD, PhD
Great Neck, New York, United States, 11021
University Urology Associates
New York, New York, United States, 10016
Michael A. Werner
Purchase, New York, United States, 10577
United States, Oregon
Sunstone Medical Research
Medford, Oregon, United States, 97504
United States, Pennsylvania
Urologic Consultants of Southeast Pennsylvania
Bala Cynwyd, Pennsylvania, United States, 19004
United States, Texas
Research Across America
Carrollton, Texas, United States, 75010
Research Across America
Dallas, Texas, United States, 75234
United States, Washington
University of Washington
Seattle, Washington, United States, 98195
University of Bonn, Clinic for Dermatology and Allergy
Bonn, Germany, 53105
University of Halle, Center for Reproduction and Andrology
Halle, Germany, 06120
Praxis Dr. Szymula
Leipzig, Germany, 04105
Praxis Dr. Schulze
Markkleeberg, Germany, 04416
University of Muenster, Center for Reproduction and Andrology
Muenster, Germany, 48149
Sponsors and Collaborators
Clarus Therapeutics, Inc.
Principal Investigator: Ronald Swerdloff, MD University of California, Los Angeles
  More Information

Responsible Party: Clarus Therapeutics, Inc. Identifier: NCT01699178     History of Changes
Other Study ID Numbers: CLAR-12010
Study First Received: September 5, 2012
Last Updated: December 17, 2013

Additional relevant MeSH terms:
Gonadal Disorders
Endocrine System Diseases
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents processed this record on September 19, 2017